



# PRESS RELEASE

**ASN Contact:** Christine Feheley  
(202) 640-4638 | [cfeheley@asn-online.org](mailto:cfeheley@asn-online.org)

**EMBARGOED FOR RELEASE UNTIL  
OCTOBER 25, 2024 AT 4:30 PM PDT**

## Do Certain Diabetes Drugs Increase the Risk of Acute Kidney Injury in Patients Taking Anti-Cancer Therapies?

### Highlights

- Although glucagon-like peptide-1-receptor agonists have been linked to acute kidney injury in prior studies, a recent analysis found no such association in patients with cancer who were taking these medications in addition to their anti-cancer therapy.
- Results from the study will be presented at ASN Kidney Week 2024 October 23–27.

**San Diego, CA (October 25, 2024)** — Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear. Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies. The findings will be presented at ASN Kidney Week 2024 October 23–27.

For the study, investigators analyzed medical records of patients who were treated with anti-cancer medications including cytotoxic, targeted immunotherapies over a 1-year period.

Among 14,783 patients, 9% were treated with a GLP-1RA while taking anti-cancer drugs. AKI occurred in 7.2% of those exposed to GLP-1RA versus 6.4% of those with no GLP-1RA exposure.

“Given the cardiovascular and anti-diabetic benefits of GLP-1RA, we suggest that these agents can be safely continued during administration of anti-cancer therapy,” said corresponding author Swetha Rani Kanduri, MD, of Ochsner Health. “We invite prospective studies to further elaborate on the effects of GLP-1RA in patients with cancer.”

Study: “Exposure to Glucagon Like Peptide 1 Receptor Agonists (GLP-1RA) Does Not Increase the Risk of AKI Associated with Anti-Cancer Therapy”

*Join ASN and approximately 12,000 other kidney professionals from across the globe at Kidney Week 2024 in San Diego, CA. The world's premier nephrology meeting, Kidney Week, provides participants with exciting and challenging opportunities to exchange knowledge, learn the latest scientific and medical advances, and listen to engaging and provocative discussions with leading experts in the field. Early programs begin on October 23, followed by the Annual Meeting from October 24-27. Follow the conversation at #KidneyWk.*

**About ASN**

*Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge and advocating for the highest quality care for patients. ASN has nearly 21,000 members representing 140 countries. For more information, visit [www.asn-online.org](http://www.asn-online.org) and follow us on [Facebook](#), [X](#), [LinkedIn](#), and [Instagram](#).*

###